Results 11 to 20 of about 53,202 (260)
GLP-1RA Use and Thyroid Cancer Risk.
JAMA Otolaryngol Head Neck SurgThe increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RA) demands a better understanding of their association with thyroid cancer. To estimate the risk of incident thyroid cancer among adults with type 2 diabetes being treated with GLP ...
Brito JP +12 more
europepmc +4 more sources
Sex-Based Differences in SGLT2i and GLP-1RA Use and Mortality in T2DM with Atherosclerotic Cardiovascular Disease. [PDF]
BiomedicinesBackground: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) remain underused in routine practice, particularly among women.
Vaknin-Assa H +9 more
europepmc +3 more sources
The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. [PDF]
J Eur Acad Dermatol VenereolGlucagon-like peptide 1 receptor agonists (GLP-1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP-1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and ...
Paschou IA +5 more
europepmc +6 more sources
GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects. [PDF]
J Clin InvestGlucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an essential drug class for treating type 2 diabetes, offering proven benefits in glycemic control, weight reduction, and cardiovascular and renal protection.
Cardoso P, Dennis JM, Pearson ER.
europepmc +10 more sources
GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI
Frontiers in EndocrinologyBackgroundGlucagon-like peptide-1 receptor agonist(GLP-1RA) is commonly used in patients with cardiovascular disease due to its significant improvement in the prognosis of atherosclerotic cardiovascular disease (ASCVD).
Ling Xu, Dan Zhu
doaj +2 more sources
Cardiometabolic improvements, sleep apnea reduction, and biomarker modulation under dual GLP-1RA and SGLT2i therapy: a prospective study [PDF]
PharmaciaThis prospective cohort study explored the cardiometabolic, sleep-related, and biomarker effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium–glucose cotransporter-2 inhibitors (SGLT2i), and their combination in patients with heart ...
Petar Kalaydzhiev +9 more
doaj +5 more sources
Frontiers in Endocrinology, 2022 Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI ...
Shichao Dong, Chuan Sun
doaj +1 more source
Decoding the hallmarks of GLP-1RA weight-loss super-responders. [PDF]
Biol Methods ProtocAbstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135 349 individuals treated with semaglutide and tirzepatide formulations and stratified them as “super responders” (>
Venkatakrishnan AJ +2 more
europepmc +2 more sources
Semaglutide seems to be more effective the other GLP-1Ras [PDF]
Annals of Translational Medicine, 2017 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced as treatment options for type 2 diabetes (T2DM) in 2005 (1). They have become popular because of their efficacy and durability in relation to glycaemic control, and their low risk of hypoglycaemia in combination with weight loss in most patients (2,3).
Holst, Jens Juul, Madsbad, Sten
openaire +3 more sources
European Psychiatry, 2023 Background Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs).
Congqin Chen +3 more
doaj +1 more source